ALEXIS Biochemicals: Sinefungin

Advanced Search

You are here: Product Lines > DNA Regulation / Transcription > Antibiotics - DNA Regulation / Transcription

Antibiotics - DNA Replication Inhibitors

Antibiotics - Topoisomerase Inhibitors

Other Antibiotics - DNA Regulation / Transcription

ALX-380-293

Revised 04-Aug-08

Lomefloxacin . hydrochloride
SYNONYMS	1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-293-G001		1 g	20.00 USD
ALX-380-293-G005		5 g	80.00 USD

Product Specification

FORMULA:	C₁₇H₁₉F₂N₃O₃ . HCl
MW:	351.4 . 36.5
CAS NUMBER:	98079-52-8
MERCK INDEX:	14: 5562
RTECS:	VB1997500
PURITY:	≥89% (Assay)
APPEARANCE:	White to off-white crystalline powder.
SOLUBILITY:	Soluble in 1M sodium hydroxide (50mg/ml); sparingly soluble in water; insoluble in 100% ethanol.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Protect from light.
HAZARD:	HARMFUL.

Product Description

Fluoroquinolone with broad spectrum activity against Gram-negative and Gram-positive bacteria. Inhibits bacterial DNA-gyrase (topoisomerase).

Product Specific Literature References

Mechanism of action of lomefloxacin: L.J. Piddock, et al.; Antimicrob. Agents Chemother. 34, 1088 (1990) Abstract; Full Text
Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model: C. Rustige & B. Wiedemann; Antimicrob. Agents Chemother. 34, 1107 (1990) Abstract; Full Text

Further Categories Containing This Product:

Antibiotics - Topoisomerase Inhibitors • Antibiotics - DNA Replication Inhibitors

ALX-380-023

Revised 19-Oct-07

Mitomycin C
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - DNA Replication Inhibitors

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-023-M005		5 mg	98.00 USD
ALX-380-023-M010		10 mg	185.00 USD

Product Specification

FORMULA:	C₁₅H₁₈N₄O₅
MW:	334.3
CAS NUMBER:	50-07-7
MERCK INDEX:	14: 6215
RTECS:	CN0700000
SOURCE/HOST:	Isolated from Streptomyces caespitosus.
PURITY:	≥98%
APPEARANCE:	Blue-violet crystals.
SOLUBILITY:	Soluble in water or methanol.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+4°C
HANDLING:	Protect from light.
HAZARD:	TOXIC. MAY BE CARCINOGENIC.

Product Description

Antitumor antibiotic. Inhibitor of DNA synthesis, nuclear division and cancer cells. DNA intercalating agent. Apoptosis inducer.

Product Specific Literature References

Mitomycin, a new antibiotic from Streptomyces. I: T. Hata, et al.; J. Antibiot. (Tokyo) 9, 141 (1956) Abstract
S.K. Carter & S.T. Crooke ; 'Mitomycin C. Current Status and New Developments', Academic Press, New York (1979)
Revised absolute configuration of mitomycin C. X-ray analysis of 1-N-(p-bromobenzoyl)mitomycin C: K. Shirahata & N. Hirayama; JACS 105, 7199 (1983)
Sequence-specific DNA damage induced by reduced mitomycin C and 7-N-(p- hydroxyphenyl)mitomycin C: K. Ueda and T. Komano; Nucl. Acids Res. 12, 6673 (1984) Abstract
Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA: M. Tomasz, et al.; Science 235, 1204 (1987) Abstract
The chemistry of DNA modification by antitumor antibiotics: J.F. Fisher & P.A. Aristoff; Prog. Drug Res. 32, 411 (1988) Abstract
DNA sequence specificity of mitomycin cross-linking: S.P. Teng, et al.; Biochemistry 28, 3901 (1989) Abstract
Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C: S. Kawasaki, et al.; J. Cancer Res. 83, 899 (1992) Abstract
Genetic evidence for an activator required for induction of pectin lyase in Erwinia carotovora subsp. carotovora by DNA-damaging agents: J.L. McEvoy, et al.; J. Bacteriol. 174, 5471 (1992) Abstract
Elevated DT-diaphorase activity and messenger RNA content in human non- small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl: A.M. Malkinson, et al.; Cancer Res. 52, 4752 (1992) Abstract
Mitomycins: J. Verweij, et al.; Cancer Chemother. Biol. Response Modif. 18, 46 (1999) Abstract
Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95- independent manner in human gastric adenocarcinoma cells: I.C. Park, et al.; Cancer Lett. 158, 125 (2000) Abstract
Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis: C.T. Hsueh, et al.; Cancer Chemother. Pharmacol. 45, 389 (2000) Abstract
DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling: A.R. Tee & C.G. Proud; Oncogene 19, 3021 (2000) Abstract
Re-evaluation of tumor-specific cytotoxicity of mitomycin C, bleomycin and peplomycin: M. Sasaki, et al.; Anticancer Res. 26, 3373 (2006) Abstract
Activation of the S phase DNA damage checkpoint by mitomycin C: E. Mladenov, et al.; J. Cell. Physiol. 211, 468 (2007) Abstract

Further Categories Containing This Product:

Antitumor Agents (Apoptosis Inducers) • Antitumor Antibiotics • Antibiotics - Apoptosis Inducers & Inhibitors • Antitumor Agents (DNA Interaction & Gene Regulation) • DNA Replication Inhibitors

ALX-804-624

Revised 20-Jun-05

Monoclonal Antibody to Doxorubicin (MAD11)
SYNONYMS	anti-DXR MAb (MAD11) anti-14-Hydroxydaunomycin MAb (MAD11) anti-Adriamycin MAb (MAD11)
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antitumor Antibiotics

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-804-624-C100		100 µg	320.00 USD

Product Specification

CLONE:	MAD11
ISOTYPE:	Mouse IgG2
CONCENTRATION:
FORMULATION:	Liquid. Purified antibody containing 150mM sodium chloride and 0.02% sodium azide, pH 7.4.
IMMUNOGEN:	Doxorubicin-BSA.
SPECIFICITY:	Recognizes anthracycline compounds including doxorubicin analogs and derivatives.
APPLICATION:	ELISA Immunohistochemistry Functional Application: In vivo antidotic effect.
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	+4°C
HANDLING:	Do not freeze.

Product Specific Literature References

Monoclonal antibodies against doxorubicin: A. Balsari, et al.; Int. J. Cancer 42, 798 (1988) Abstract
A new monoclonal antibody recognizing anthracyclinic molecule: A. Balsari, et al.; Anticancer Res. 10, 129 (1990) Abstract
Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin: A. Balsari, et al.; Int. J. Cancer 47, 889 (1991) Abstract
An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug: A. Sardini, et al.; Int. J. Cancer 50, 617 (1992) Abstract
Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies: A.L. Balsari, et al.; FASEB J. 8, 226 (1994) Abstract
Effect of a bifunctional monoclonal antibody directed against a tumor marker and doxorubicin on the growth of epidermoid vulvar carcinoma grafted in athymic mice: D. Morelli, et al.; Cell Biophys. 24-25, 119 (1994) Abstract
Relevance of antibody valency in EGF receptor modulation: D. Morelli, et al.; Scand. J. Immunol. 39, 453 (1994) Abstract
Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice: D. Morelli, et al.; Cancer Res. 56, 2082 (1996) Abstract
Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats: R. Cece, et al.; Lab. Invest. 75, 601 (1996) Abstract
Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice: D. Morelli, et al.; Br. J. Cancer 75, 656 (1997) Abstract
Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice: A. Balsari, et al.; Br. J. Cancer 85, 1964 (2001) Abstract
Role of proliferation in HER2 status predicted response to doxorubicin: M. Campiglio, et al.; Int. J. Cancer 105, 568 (2003) Abstract

Further Categories Containing This Product:

Cancer Other Products • Topoisomerases Other Products • Antibiotics - Topoisomerase Inhibitors • Monoclonal Antibodies

ALX-380-294

Revised 15-Apr-08

Nadifloxacin
SYNONYMS	9-Fluoro-6,7-dihydro-8-(4-hydroxypiperidino)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid Jinofloxacin OPC-7251

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-294-M250		250 mg	90.00 USD
ALX-380-294-G001		1 g	270.00 USD

Product Specification

FORMULA:	C₁₉H₂₁FN₂O₄
MW:	360.4
CAS NUMBER:	124858-35-1
MERCK INDEX:	14: 6345
PURITY:	≥98% (Assay)
APPEARANCE:	White to yellow crystalline solid.
SOLUBILITY:	Soluble in DMSO.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C

Product Description

Fluoroquinolone with broad spectrum activity against Gram-negative and Gram-positive bacteria. Inhibits the generation of O^2- and OH radicals by neutrophils. Inhibits the production of inflammtory cytokines.

Product Specific Literature References

Studies on antibacterial agents. I. Synthesis of substituted 6,7-dihydro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids: H. Ishikawa, et al.; Chem. Pharm. Bull. 37, 2103 (1989) Abstract
Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base: I. Kurokawa, et al.; J. Am. Acad. Dermatol. 25, 674 (1991) Abstract
Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris: K. Vogt, et al.; Eur. J. Clin. Microbiol. Infect. Dis. 11, 943 (1992) Abstract
Effect of nadifloxacin on neutrophil functions: H. Akamatsu, et al.; J. Int. Med. Res. 23, 19 (1995) Abstract
Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus: N. Oizumi, et al.; J. Infect. Chemother. 7, 191 (2001) Abstract
Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections: P. Nenoff, et al.; Chemotherapy 50, 196 (2004) Abstract
Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes: K. Kuwahara, et al.; J. Dermatol. Sci. 38, 47 (2005) Abstract
Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771: M.R. Jacobs & P.C. Appelbaum; Expert Opin. Pharmacother. 7, 1957 (2006) Abstract

Further Categories Containing This Product:

Antibiotics - Topoisomerase Inhibitors • Antibiotics - DNA Replication Inhibitors • Antibiotics for Inflammation Research

ALX-380-088

Revised 30-Jul-08

Netropsin . dihydrochloride
SYNONYMS	4-([((Aminoiminomethyl)amino)acetyl)amino)-N-(5-(((3-amino-3-iminopropyl)amino)carbonyl]-1-methyl-1H-pyrrol-3-yl)-1-methyl-1H-pyrrole-3-carboxamide
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antitumor Antibiotics

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-088-M005		5 mg	40.00 USD

Product Specification

FORMULA:	C₁₈H₂₆N₁₀O₃ . 2HCl
MW:	430.5 . 73.0
CAS NUMBER:	63770-20-7 (hydrochloride)
RTECS:	DW2973000
SOURCE/HOST:	Isolated from Streptomyces netropsis.
PURITY:	≥93% (HPLC)
APPEARANCE:	Faint yellow powder.
SOLUBILITY:	Soluble in alcohols or water.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Protect from light.
HAZARD:	HARMFUL.

Product Description

Nucleic acid binding ligand. Binds to A-T-rich regions of the minor groove of DNA.

Product Specific Literature References

Netropsin, a New Antibiotic Produced by a Streptomyces: A.C. Finlay et al.; J. Am. Chem. Soc. 73, 341 (1951)
Efficient Total Syntheses of the Oligopeptide Antibiotics Netropsin and Distamycin: J.W. Lown et al.; J. Org. Chem. 50, 3774 (1985)
Sequence and structural selectivity of nucleic acid binding ligands: J. Ren & J.B. Chaires; Biochemistry 38, 16067 (1999) Abstract
Molecular modelling of the interaction of carbocyclic analogues of netropsin and distamycin with d(CGCGAATTCGCG)2: K. Bielawski, et al.; Acta Biochim. Pol. 47, 855 (2000) Abstract
Recent developments in sequence selective minor groove DNA effectors: B.S. Reddy, et al.; Curr. Med. Chem. 8, 475 (2001), (Review) Abstract

Further Categories Containing This Product:

Other Antibiotics - DNA Regulation / Transcription • Antibiotics - Antiviral / Anti-HIV

ALX-380-295

Revised 15-Apr-08

Norfloxacin
SYNONYMS	1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-295-G001		1 g	20.00 USD
ALX-380-295-G005		5 g	50.00 USD

Product Specification

FORMULA:	C₁₆H₁₈FN₃O₃
MW:	319.3
CAS NUMBER:	70458-96-7
MERCK INDEX:	14: 6700
RTECS:	VB2005000
PURITY:	≥98% (Assay)
APPEARANCE:	White to yellow crystalline solid.
SOLUBILITY:	Slightly soluble in water, 100% ethanol or methanol.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C

Product Description

Fluoroquinolone antibacterial agent. Inhibits bacterial DNA replication. Blocks DNA replication by interfering with an ATP-induced structural transition of DNA complexed with DNA gyrase (topoisomerase). Effective against Gram-negative bacteria; less effective against Gram-positive bacteria. Potentially anxiogenic.

Product Specific Literature References

Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids: H. Koga, et al.; J. Med. Chem. 23, 1358 (1980) Abstract
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections: K. Hirai, et al.; Antimicrob. Agents Chemother. 19, 188 (1981) Abstract; Full Text
In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa: J. Downs, et al.; Antimicrob. Agents Chemother. 21, 670 (1982) Abstract
Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents: H.H. Gadebusch, et al.; Infection 10, 41 (1982) Abstract
Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin: S.R. Crider, et al.; N. Engl. J. Med. 311, 137 (1984) Abstract
Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use: B. Holmes, et al.; Drugs 30, 482 (1985) Abstract
Norfloxacin: clinical pharmacology and clinical use: R.C. Rowen, et al.; Pharmacotherapy 7, 92 (1987) Abstract
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats: M. Chenel, et al.; Antimicrob. Agents Chemother. 47, 1952 (2003) Abstract; Full Text
Norfloxacin-induced DNA gyrase cleavage complexes block Escherichia coli replication forks, causing double-stranded breaks in vivo: J.R. Pohlhaus & K.N. Kreuzer; Mol. Microbiol. 56, 1416 (2005) Abstract; Full Text
Anxiogenic potential of ciprofloxacin and norfloxacin in rats: S. Sen, et al.; Singapore Med. J. 48, 1028 (2007) Abstract; Full Text

Related Products

ALX-380-295

Norfloxacin

Further Categories Containing This Product:

Antibiotics - Topoisomerase Inhibitors • Antibiotics - DNA Replication Inhibitors

ALX-380-093

Revised 16-Jun-08

Novobiocin . sodium salt
SYNONYMS	Albamycin Streptonivicin N-[7-[[3-O-Aminocarbonyl-6-deoxy-5-C-methyl-4-O-β-L-lyxo-hexapyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl)benzamide
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Other Signal Transduction Pathway Modulators

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-093-G001		1 g	30.00 USD

Product Specification

FORMULA:	C₃₁H₃₅N₂O₁₁ . Na
MW:	611.6 . 23.0
CAS NUMBER:	1476-53-5
MERCK INDEX:	14: 6722
RTECS:	RD5425000
PURITY:	≥95%
APPEARANCE:	White to pale yellow solid.
SOLUBILITY:	Soluble in water (100mg/ml).
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+4°C
HANDLING:	Protect from light.
HAZARD:	HARMFUL. IRRITANT.

Product Description

Antibiotic. Inhibitor of HSP90. Interacts with the C-terminal ATP-binding domain of HSP90 in contrast to the benzoquinone ansamycins 17-AAG (Prod. No. ALX-380-091), geldanamycin (Prod. No. ALX-380-054), herbimycin A (Prod. No. ALX-350-029), and the chemically unrelated radicicol (Prod. No. ALX-380-092), which bind to the N-terminal ATP-binding site of HSP90. Inhibitor of DNA gyrase. Useful for the production of positively supercoiled plasma DNA, targeting the nucleotide-binding site of gyrase B. Inhibits retrovirus RNA-dependent DNA polymerase. Potent inhibitor of ADP ribosylation. Inhibits LPS-induced production of pro-inflammatory cytokines, such as TNF-α, IL-1, IL-6 and IL-10. Inhibits protein synthesis and alters the phosphorylation state of several cytosolic proteins. Reverses etoposide resistance in non-P-glycoprotein expressing multidrug resistant (MDR) tumor cell lines. Inducer of CD38 on cells of the myelomonocytic lineage. Forms ion channels in lipid bilayers.

Product Specific Literature References

Novobiocin-a specific inhibitor of semiconservative DNA replication in permeabilized Escherichia coli cells: W.L. Staudenbauer; J. Mol. Biol. 96, 201 (1975) Abstract
Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase: M. Gellert, et al.; PNAS 73, 4474 (1976) Abstract; Full Text
Energy coupling in DNA gyrase and the mechanism of action of novobiocin: A. Sugino, et al.; PNAS 75, 4838 (1978) Abstract; Full Text
Effect of novobiocin and other DNA gyrase inhibitors on virus replication and DNA synthesis in herpes simplex virus type 1-infected BHK cells: B. Francke and J. Margolin; J. Gen. Virol. 52, 401 (1981) Abstract; Full Text
Inhibition of retrovirus RNA-dependent DNA polymerase by novobiocin and nalidixic acid: Y. Sumiyoshi, et al.; J. Gen. Virol. 64, 2329 (1983) Abstract
Positively supercoiled plasmid DNA is produced by treatment of Escherichia coli with DNA gyrase inhibitors: D. Lockshon and D.R. Morris; Nucleic Acids Res. 11, 2999 (1983) Abstract
Structure-activity relationships in DNA gyrase inhibitors: S. Radl; Pharmacol. Ther. 48, 1 (1990), (Review) Abstract
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin: G. Rappa, et al.; Cancer Res. 53, 58487 (1993) Abstract
The properties of ion channels formed by the coumarin antibiotic, novobiocin, in lipid bilayers: A.M. Feigin, et al.; Biochim. Biophys. Acta 1234, 43 (1995) Abstract
Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin: J. Sekiguchi, et al.; J. Biol. Chem. 271, 2313 (1996) Abstract; Full Text
Immunomodulating properties of the antibiotic novobiocin in human monocytes: A. Luhrmann, et al.; Antimicrob. Agents Chemother. 42, 1911 (1998) Abstract; Full Text
Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins: M.G. Marcu, et al.; J. Natl. Cancer Inst. 92, 242 (2000) Abstract
The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone: M.G. Marcu, et al.; J. Biol. Chem. 275, 37181 (2000) Abstract; Full Text
Novobiocin is a novel inducer of CD38 on cells of the myelomonocytic lineage: A. Thiele, et al.; Biochim. Biophys. Acta 1542, 32 (2002) Abstract
Evidence that the novobiocin-sensitive ATP-binding site of the heat shock protein 90 (hsp90) is necessary for its autophosphorylation: T. Langer, et al.; Cell Biol. Int. 26, 653 (2002) Abstract
Alteration of Escherichia coli topoisomerase IV to novobiocin resistance: C.D. Hardy and N.R. Cozzarelli; Antimicrob. Agents Chemother. 47, 941 (2003) Abstract; Full Text
Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance: C.H. Gross, et al.; Antimicrob. Agents Chemother. 47, 1037 (2003) Abstract; Full Text
A coumermycin/novobiocin-regulated gene expression system: H.F. Zhao, et al.; Hum. Gene Ther. 14, 1619 (2003) Abstract
Destabilization of the non-pathogenic, cellular prion-protein by a small molecular drug: H.J. Ochel and G. Gademann; Antivir. Ther. 9, 441 (2004)

FORMULA:	C₁₆H₁₈FN₃O₃ . C₆H₅NO₂
MW:	319.3 . 123.1
CAS NUMBER:	11803-81-9
PURITY:	≥98% (Assay)
APPEARANCE:	White to yellow crystalline solid.
SOLUBILITY:	Soluble in water.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C